Zonisamid

Zonisamid
Klinički podaci
Prodajno ime	Exceglan, Excegram, Excegran, Zonegran
Drugs.com	Monografija
Način primene	Oralno
Farmakokinetički podaci
Poluvreme eliminacije	63 h
Identifikatori
CAS broj	68291-97-4
ATC kod	N03AX15 (WHO)
PubChem	CID 5734
DrugBank	DB00909
ChemSpider	5532
KEGG	C07504
ChEBI	CHEBI:10127
ChEMBL	CHEMBL750
Hemijski podaci
Formula	C8H8N2O3S
Molarna masa	212,226
	SMILES NS(=O)(=O)CC1=NOC2=CC=CC=C12; ;
	InChI InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12) ; Key:UBQNRHZMVUUOMG-UHFFFAOYSA-N ;
Fizički podaci
Tačka topljenja	161—163 °C (322—325 °F)

Zonisamid je organsko jedinjenje, koje sadrži 8 atoma ugljenika i ima molekulsku masu od 212,226 Da.^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]^[10]^[11]^[12]

Osobine[uredi | uredi izvor]

Osobina	Vrednost
Broj akceptora vodonika	3
Broj donora vodonika	1
Broj rotacionih veza	2
Particioni koeficijent^[13] (ALogP)	0,4
Rastvorljivost^[14] (logS, log(mol/L))	-2,2
Polarna površina^[15] (PSA, Å²)	94,6

Reference[uredi | uredi izvor]

^ Murata, M.; Horiuchi, E.; Kanazawa, I. (decembar 2001). „Zonisamide has beneficial effects on Parkinson's disease patients”. Neuroscience Research. 41 (4): 397—9. PMID 11755227. S2CID 41685120. doi:10.1016/s0168-0102(01)00298-x. CS1 održavanje: Format datuma (veza)
^ Gadde, K. M.; Franciscy, D. M.; Wagner Hr, 2nd; Krishnan, K. R. (2003-04-09). „Zonisamide for weight loss in obese adults: A randomized controlled trial”. JAMA. 289 (14): 1820—5. PMID 12684361. doi:10.1001/jama.289.14.1820.
^ Hasegawa, H. (maj 2004). „Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: A retrospective, open label, uncontrolled study in a VA hospital”. Current Medical Research and Opinion. 20 (5): 577—80. PMID 15140322. S2CID 43580909. doi:10.1185/030079904125003313. CS1 održavanje: Format datuma (veza)
^ Leppik, I. E. (2004). „Zonisamide: Chemistry, mechanism of action, and pharmacokinetics”. Seizure. 13 Suppl 1: S5—9; discussion S10. PMID 15511691. S2CID 13458791. doi:10.1016/j.seizure.2004.04.016.
^ Ueda, Y.; Doi, T.; Tokumaru, J.; Willmore, L. J. (2003). „Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures”. Brain Research. Molecular Brain Research. 116 (1–2): 1—6. PMID 12941455. doi:10.1016/s0169-328x(03)00183-9.
^ Farooq, M. U.; Moore, P. W.; Bhatt, A.; Aburashed, R.; Kassab, M. Y. (septembar 2008). „Therapeutic role of zonisamide in neuropsychiatric disorders”. Mini Reviews in Medicinal Chemistry. 8 (10): 968—75. PMID 18782051. doi:10.2174/138955708785740643. CS1 održavanje: Format datuma (veza)
^ Schulze-Bonhage, A. (januar 2010). „Zonisamide in the treatment of epilepsy”. Expert Opinion on Pharmacotherapy. 11 (1): 115—26. PMID 20001433. S2CID 24881172. doi:10.1517/14656560903468728. CS1 održavanje: Format datuma (veza)
^ Kothare, S. V.; Kaleyias, J. (april 2008). „Zonisamide: Review of pharmacology, clinical efficacy, tolerability, and safety”. Expert Opinion on Drug Metabolism & Toxicology. 4 (4): 493—506. PMID 18433351. S2CID 71773943. doi:10.1517/17425255.4.4.493. CS1 održavanje: Format datuma (veza)
^ Peters, D. H.; Sorkin, E. M. (maj 1993). „Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy”. Drugs. 45 (5): 760—87. PMID 7686468. doi:10.2165/00003495-199345050-00010. CS1 održavanje: Format datuma (veza)
^ Sobieszek, G.; Borowicz, K. K.; Kimber-Trojnar, Z.; Małek, R.; Piskorska, B.; Czuczwar, S. J. (2003). „Zonisamide: A new antiepileptic drug”. Polish Journal of Pharmacology. 55 (5): 683—9. PMID 14704463.
^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126. uredi
^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958. uredi
^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t. uredi
^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e. уреди

Literatura[uredi | uredi izvor]

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze[uredi | uredi izvor]

Zonisamide

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Murata, M.; Horiuchi, E.; Kanazawa, I. (decembar 2001). „Zonisamide has beneficial effects on Parkinson's disease patients”. Neuroscience Research. 41 (4): 397—9. PMID 11755227. S2CID 41685120. doi:10.1016/s0168-0102(01)00298-x. CS1 održavanje: Format datuma (veza)

[2] Gadde, K. M.; Franciscy, D. M.; Wagner Hr, 2nd; Krishnan, K. R. (2003-04-09). „Zonisamide for weight loss in obese adults: A randomized controlled trial”. JAMA. 289 (14): 1820—5. PMID 12684361. doi:10.1001/jama.289.14.1820.

[3] Hasegawa, H. (maj 2004). „Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: A retrospective, open label, uncontrolled study in a VA hospital”. Current Medical Research and Opinion. 20 (5): 577—80. PMID 15140322. S2CID 43580909. doi:10.1185/030079904125003313. CS1 održavanje: Format datuma (veza)

[4] Leppik, I. E. (2004). „Zonisamide: Chemistry, mechanism of action, and pharmacokinetics”. Seizure. 13 Suppl 1: S5—9; discussion S10. PMID 15511691. S2CID 13458791. doi:10.1016/j.seizure.2004.04.016.

[5] Ueda, Y.; Doi, T.; Tokumaru, J.; Willmore, L. J. (2003). „Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures”. Brain Research. Molecular Brain Research. 116 (1–2): 1—6. PMID 12941455. doi:10.1016/s0169-328x(03)00183-9.

[6] Farooq, M. U.; Moore, P. W.; Bhatt, A.; Aburashed, R.; Kassab, M. Y. (septembar 2008). „Therapeutic role of zonisamide in neuropsychiatric disorders”. Mini Reviews in Medicinal Chemistry. 8 (10): 968—75. PMID 18782051. doi:10.2174/138955708785740643. CS1 održavanje: Format datuma (veza)

[7] Schulze-Bonhage, A. (januar 2010). „Zonisamide in the treatment of epilepsy”. Expert Opinion on Pharmacotherapy. 11 (1): 115—26. PMID 20001433. S2CID 24881172. doi:10.1517/14656560903468728. CS1 održavanje: Format datuma (veza)

[8] Kothare, S. V.; Kaleyias, J. (april 2008). „Zonisamide: Review of pharmacology, clinical efficacy, tolerability, and safety”. Expert Opinion on Drug Metabolism & Toxicology. 4 (4): 493—506. PMID 18433351. S2CID 71773943. doi:10.1517/17425255.4.4.493. CS1 održavanje: Format datuma (veza)

[9] Peters, D. H.; Sorkin, E. M. (maj 1993). „Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy”. Drugs. 45 (5): 760—87. PMID 7686468. doi:10.2165/00003495-199345050-00010. CS1 održavanje: Format datuma (veza)

[10] Sobieszek, G.; Borowicz, K. K.; Kimber-Trojnar, Z.; Małek, R.; Piskorska, B.; Czuczwar, S. J. (2003). „Zonisamide: A new antiepileptic drug”. Polish Journal of Pharmacology. 55 (5): 683—9. PMID 14704463.

[11] Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126. uredi

[12] David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958. uredi

[13] Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.

[14] Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t. uredi

[15] Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e. уреди

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]